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To date, the external validity of randomized controlled trials (RCTs) on Alzheimer’s disease 
(AD) has been assessed only considering monodimensional variables. Nevertheless, 
looking at isolated and single characteristics cannot guarantee a sufficient level of 
appreciation of the AD patients’ complexity. The only way to understand whether the 
two worlds (i.e., research and clinics) deal with the same type of patients is to adopt 
multidimensional approaches more holistically reflecting the biological age of the indi-
vidual. In the present study, we compared measures of frailty/biological aging [assessed 
by a Frailty Index (FI)] of a sample of patients with AD resulted eligible and subsequently 
included in phase III RCTs compared to patients referring to the same clinical service, but 
not considered for inclusion. The “RCT sample” and the “real world sample” were found 
to be statistically similar for all the considered sociodemographic and clinical variables. 
Nevertheless, the “real world sample” was found to be significantly frailer compared to 
the “RCT sample,” as indicated by higher FI scores [0.28 (SD 0.1) vs. 0.17 (SD 0.1); 
p <  0.001, respectively]. Moreover, when assessing the relationship between FI and 
age, we found that the correlation was almost null in the “RCT sample” (Spearman’s 
r = 0.01; p = 0.98), while it was statistically significant in the “real world sample” (r = 0.49; 
p = 0.02). The application of too rigid designs may result in the poor representativeness 
of RCT samples. It may even imply the study of a condition biologically different from 
that observed in the “real world.” The adoption of multidimensional measures capable 
to capture the individual’s biological age may facilitate evaluating the external validity of 
clinical studies, implicitly improving the interpretation of the results and their translation 
in the clinical arena.
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inTrODUcTiOn
Randomized controlled trials (RCTs) represent the gold standard for establishing the efficacy and 
safety/tolerability of medical interventions. Besides providing information concerning clinical and 
therapeutic outcomes, RCTs should also try to generate messages that are externally valid or gener-
alizable as much as possible. In other words, they should provide information that can be translated 
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from the relatively small group of RCT participants to a larger 
scale population (1). Unfortunately, the rigid and idealized condi-
tions typical of RCTs may often compromise the transferability 
of the study findings to the “real world” clinical practice, finally 
affecting their usefulness. In particular, if the RCT eligibility 
criteria are too selective (in order to maximize the focus on a 
specific aspect of research), the representativeness of the sampled 
population and the following generalizability of the results will 
be challenged.
Alzheimer’s disease (AD) is growingly indicated as a research 
priority (2). To date, there are more than 140 phase II–IV studies 
currently exploring the efficacy of different interventions with the 
aim of improving the clinical manifestations of the disease and/
or positively influencing its natural course (source: clinicaltrials.
gov). The external validity of RCTs on AD has repeatedly been 
debated. Specifically, a substantial discrepancy has been shown 
between patients enrolled in RCTs and the patients’ population 
which should benefit from the studies results (3, 4). Moreover, 
there is a relative lack of information about the comparability of 
these two populations in terms of clinical and pharmacological 
characteristics (5). At the same time, it seems that RCTs on AD 
pay special attention to other aspects for selecting the popula-
tions of interest. For example, a good representativeness with 
regard to sex distribution has been reported for most of available 
RCTs (6).
It is possible that relying on specific sociodemographic factors 
(e.g., age and sex) and/or crude clinical parameters (e.g., number 
of diseases, type of comorbidities, concomitant medications) only 
provides a monodimensional (and not comprehensive) evaluation 
of the RCTs participants’ health status. Looking at isolated and 
single variables cannot guarantee a sufficient level of appreciation 
of the AD patients’ complexity. Moreover, it will preclude a fair 
comparability between RCTs participants and the overall popula-
tion of patients with AD. The only way to understand whether the 
two worlds (i.e., research and clinical practice) deal with the same 
type of patients is to adopt a multidimensional approach relying 
on measures/variables that are able to more holistically reflecting 
the biological age of the individual.
In the present study, we assess the biological aging [measured 
by a Frailty Index (FI)] presented by a sample of AD patients 
resulted eligible and subsequently included in phase III RCTs 
compared to patients referring to the same clinical service, but 
not considered for inclusion.
MaTerials anD MeThODs
Participants
The present analyses were conducted by retrospectively reviewing 
the clinical charts of patients with AD attending the Department 
of Neurology and Psychiatry of the “Sapienza” University of Rome 
(Italy) between January 2015 and January 2017.
We compared the clinical and sociodemographic characteris-
tics of two groups of patients, identified as follows:
 – The “RCTs sample” was composed by patients meeting the 
following inclusion criteria shared by two phase III RCTs 
ongoing at our department, both exploring the efficacy and 
safety/tolerability of passive immunization interventions 
against amyloid: (1) age between 55 and 90 years; (2) diagnosis 
of probable AD dementia [NIA-AA criteria (7)]; (3) Mini-
Mental State Examination (MMSE) score ranging between 
20 and 26; (4) absence of concurrent serious or unstable ill-
nesses (investigator’s opinion); and (5) positive findings at the 
amyloid positron emission tomography scan or cerebrospinal 
fluid consistent with the presence of amyloid pathology [i.e., 
probable AD dementia with evidence of the AD pathophysi-
ological process (7)].
 – The “real world” sample was composed by an equal number 
of consecutively selected, age- and MMSE-matched patients 
with AD attending our memory clinic, not enrolled in any 
RCTs. In order to mirror as much as possible the eligibility 
criteria selecting the “RCTs sample,” the following inclusion 
criteria were additionally adopted for the “real world sample”: 
(1) age between 55 and 90  years; (2) diagnosis of probable 
AD dementia (NIA-AA criteria); (3) MMSE score ranging 
between 20 and 26; and (4) absence of concurrent serious or 
unstable illnesses.
The present study did not require formal ethical approval 
in accordance with the national and institutional guidelines. 
Patients and caregivers (or legal guardians when necessary) 
provided written informed consent for allowing the utilization 
of the collected data for research purposes (as required by the 
“Policlinico Umberto I” university hospital of Rome). Data used 
in the present analyses were exclusively retrieved from medical 
charts where information was recorded as part of the standard 
clinical routine.
Frailty index
A FI was retrospectively generated from the variables available 
in the clinical charts following a standard procedure (8) by 
computing 28 age-related deficits (including signs, symptoms, 
adjudicated diagnoses, disabilities) (Table  1). Each item 
included in the FI was coded so that a value of 0 indicated the 
absence of the deficit and a value of 1 its presence. The FI was 
calculated as the ratio between the number of deficits presented 
by the individual and the number of considered deficits (i.e., 
28). Thus, the FI potentially ranged between 0 (no deficit) and 
1 (all deficits).
statistical analyses
Univariate analyses were conducted to compare the baseline 
data between the “RCT sample” and the “real world sample.” 
Spearman’s correlations were used to assess the strength and 
direction of the relationship between age and FI.
resUlTs
Overall, the “RCT sample” and the “real world sample” were 
found to be statistically similar for all the considered sociode-
mographic and clinical variables (all p values > 0.05; Table 2). 
Nevertheless, the “real world sample” was found to be significantly 
TaBle 1 | Deficits included in the computation of the 28-item Frailty Index.
 1. Hypertension
 2. Autoimmune disease
 3. Hepatic diseases
 4. Ischemic heart disease
 5. History of TIA/stroke
 6. Diabetes
 7. Focal neurological signs
 8. Renal failure
 9. Arrhythmia
10. Thyroid disease
11. Cancer
12. COPD
13. Dyslipidemia
14. Obesity (BMI ≥ 30 kg/m2)
15. Underweight (BMI < 18.5 kg/m2)
16. Urinary incontinence
17. Depression
18. Apathy (NPI)
19. Anxiety (NPI)
20. Sleep disorders
21. IADL (shopping)
22. IADL (transportation)
23. IADL (drugs)
24. IADL (money)
25. ADL (toileting)
26. ADL (eating)
27. ADL (dressing)
28. ADL (transportation)
ADL, activities of daily living; BMI, body max index; COPD, chronic obstructive 
pulmonary disease; IADL, instrumental activities of daily living; NPI, neuropsychiatric 
inventory.
TaBle 2 | Sociodemographic and clinical characteristics of the study samples.
rcT (n = 23) real world (n = 23) p
Age (years) 74.2 ± 5.7 76.6 ± 7.9 0.26
Sex (F) 52.2 56.5 0.77
Education (years) 10.1 ± 4.9 9.8 ± 5.1 0.84
BMI (kg/m2) 25.4 ± 3.2 24.5 ± 3.4 0.37
Familial history for AD 47.8 33.3 0.33
Hypertension 43.5 65.2 0.14
Diabetes 13.0 13.0 1.0
Dyslipidemia 52.2 52.2 1.0
COPD 8.7 13.0 0.64
Ischemic heart disease 8.7 4.3 0.55
MMSE 22.0 ± 1.6 22.3 ± 2.0 0.68
ADL 5.6 ± 0.6 5.2 ± 1.3 0.12
Drugs 4.9 ± 1.7 4.1 ± 2.1 0.17
Polypharmacy 34.8 39.1 0.76
Frailty Index 0.17 ± 0.1 0.28 ± 0.1  < 0.001
Data are expressed as %, or mean ± SD.
Polypharmacy was defined as taking five or more concomitant medications.
AD, Alzheimer’s disease; ADL, activities of daily living; BMI, body max index; COPD, 
chronic obstructive pulmonary disease; MMSE, Mini-Mental State Examination; RCT, 
randomized controlled trial.
FigUre 1 | (a) Frailty Index (FI) values among participants enrolled in a phase III randomized controlled trial (RCT) and attending a “real world” memory clinic.  
(B) Correlation between age and FI in the two considered samples of patients.
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frailer compared to the “RCT sample,” as indicated by higher FI 
scores [0.28 (SD 0.1) vs. 0.17 (SD 0.1); p < 0.001, respectively] 
(Figure 1A). Consistently, the majority (78.3%) of patients in the 
“real world sample” were frail [i.e., FI ≥0.25 (9)], whereas only 
26.1% of frailty prevalence was reported in the “RCT sample” 
(p < 0.001). The statistically significant difference in FI between 
the two groups was confirmed even after adjustments for age and 
sex (data available upon request).
Finally, the correlation between FI and age was tested in the 
two samples. The correlation was almost null in the “RCT sample” 
(Spearman’s r = 0.01; p = 0.98), while it was statistically significant 
in the “real world sample” (r = 0.49; p = 0.02) (Figure 1B).
DiscUssiOn
In the present study, a marked discrepancy in terms of frailty 
status/biological aging was observed between patients with 
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AD eligible for RCTs versus those evaluated in the same clini-
cal setting but not considered for inclusion. Interestingly, only 
a minority of the patients selected for phase III RCTs could be 
considered as frail, despite the fact that these persons were all 
affected by an overt dementia condition (even if of mild entity). 
On the other hand, most of patients undergoing the standard 
clinical procedures exhibited a relevant amount of chronic 
deficits. The non-significant correlation between frailty and age 
in the “RCT sample” is particularly noteworthy. The absence of 
an age-related accumulation of deficits implicitly indicates that 
the studied condition is isolated from the natural aging process. 
It means that the AD is studied without taking into account the 
progressive failure of the organism reserves due to aging. It is 
evident as such scenario (i.e., a disease unaffected by the natural 
life course) is purely theoretical and of hard reproducibility in 
the “real world”.
These results can raise doubts about the applicability of findings 
coming from RCTs on AD to the “real world” clinical practice. 
In particular, how is it possible to transfer evidence obtained in a 
population of robust individuals to a population of frail subjects 
with multiple and interacting deficits? How and to what extent 
can this discrepancy affect the efficacy and safety/tolerability 
of the tested interventions in the routine clinical practice? Our 
analyses confirm how the AD population encountered in the 
daily practice is poorly comparable with the highly selected RCT 
participants. In fact, the same target condition is identified by 
adopting different approaches, one relying on probability criteria 
(i.e., “real world”) whereas the other requires a high level of 
characterization including the demonstration in vivo of specific 
pathophysiological modifications. Such ambiguity automatically 
influences the phenotypic and biological characteristics of the 
condition of interest in the two settings, challenging their com-
parability and consistency.
Our data also confirm that the adoption of monodimensional 
variables may be inadequate for capturing the inner character-
istics of individuals affected by multiple age-related conditions. 
In fact, singularly looking at the collected sociodemographic and 
clinical data, one may suppose the similarity of our two popula-
tions, potentially leading to erroneous conclusions of adequate 
comparability and representativeness. Differently, the adoption of 
a multidimensional measure (as the FI), providing a more com-
prehensive estimate of the individual’s biological status, allowed 
to reveal substantial discrepancies between the two groups. Under 
this perspective, a comprehensive assessment of the (frail) older 
individual is necessary and may improve clinical and research 
standards (10). In this context, the condition of frailty has already 
been linked to typical pathophysiological modifications of AD 
(e.g., amyloid deposition). However, it is still unclear whether the 
demonstrated association is due to a direct (e.g., amyloid depots 
are cause of frailty) or indirect (e.g., amyloid accumulation is 
related to frailty because they are both age-related conditions) 
mechanism. Indeed, the existing literature is quite ambiguous 
at nesting the effects of the aging process in the pathophysi-
ological mechanisms leading to AD. Thus, in our study, we used 
a measure of frailty (intended as biological aging) for verifying 
the appropriate consideration of “aging” in the AD construct used 
in the clinical and research setting.
Multiple instruments are available in the literature for measur-
ing the frailty condition. We chose to rely for our study on the FI 
for multiple reasons. Differently from other tools, the FI provides 
a multidimensional assessment of the individual’s biological 
age. In other words, it is not focused on a specific domain or 
characteristic (e.g., physical function) of the health status, but 
provides a comprehensive weighting of the deficits burdening the 
organism. In this context, it is also important to mention that the 
FI is based on a quantitative (and not qualitative) approach to the 
frailty condition. This means that it can be computed relying on 
the retrospective use of already existing data collected for differ-
ent purposes. Such unique characteristic allows its computation 
without the need of modifying the clinical and research practice 
already in place (i.e., it is not based on pre-defined questions or 
items) (10, 11).
Our study has some limitations. The limited sample size does 
not consent to draw definitive conclusions on the topic. However, 
the strength and consistency of the findings may suggest the 
absence of false positive results. We considered patients enrolled 
in a limited number of specific RCTs (i.e., two). Nevertheless, 
the eligibility criteria were similar to those considered by the 
majority of the ongoing RCTs in the field. The number of deficit 
used to compute the FI in our study (i.e., 28) was lower than 
what recommended in the standard procedures (i.e., 30) (8). The 
design of our study did not allow us to explore the contribution 
of specific factors (e.g., the implicit tendency of investigators to 
recruit healthier individuals in RCTs, the willingness of patients 
to participate in the RCT, etc.) potentially explaining the observed 
differences.
In conclusion, the application of too rigid designs in RCTs 
(especially those conducted in biologically old individuals) 
may result in the poor representativeness of participants for 
the “real world” clinical population they should mirror. The 
adoption of multidimensional measures (such as the FI) capa-
ble to capture the biological age of the person may facilitate the 
evaluation of the external validity of clinical studies, implicitly 
improving the interpretation of the results and their translation 
in the clinical arena.
eThics sTaTeMenT
The present analyses were conducted only retrospectively con-
sidering data that were routinely collected in the daily clinical 
practice. No additional experimental procedure was performed 
within the study.
aUThOr cOnTriBUTiOns
MCanevelli, MCesari, and GB designed the study and wrote the 
manuscript. AT, FQ, FD, and CL participated in data collection. 
All the authors contributed to the critical interpretation of the 
findings and to the drafting of the manuscript.
5Canevelli et al. The Biases of Frailty and Biological Aging
Frontiers in Neurology | www.frontiersin.org November 2017 | Volume 8 | Article 628
reFerences
1. Rothwell PM. External validity of randomised controlled trials: “to whom do 
the results of this trial apply?” Lancet (2005) 365(9453):82–93. doi:10.1016/
S0140-6736(04)17670-8 
2. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et  al. 
Defeating Alzheimer’s disease and other dementias: a priority for European 
science and society. Lancet Neurol (2016) 15(5):455–532. doi:10.1016/
S1474-4422(16)00062-4 
3. Leinonen A, Koponen M, Hartikainen S. Systematic review: representative-
ness of participants in RCTs of acetylcholinesterase inhibitors. PLoS One 
(2015) 10(5):e0124500. doi:10.1371/journal.pone.0124500 
4. Schoenmaker N, Van Gool WA. The age gap between patients in clinical 
studies and in the general population: a pitfall for dementia research. Lancet 
Neurol (2004) 3(10):627–30. doi:10.1016/S1474-4422(04)00884-1 
5. Canevelli M, Bruno G, Vanacore N, de Lena C, Cesari M. Are we really tack-
ling the “evidence-based medicine issue” in Alzheimer’s disease? Eur J Intern 
Med (2016) 35:e29–30. doi:10.1016/j.ejim.2016.07.009 
6. Canevelli M, Quarata F, Remiddi F, Lucchini F, Lacorte E, Vanacore N, et al. 
Sex and gender differences in the treatment of Alzheimer’s disease: a system-
atic review of randomized controlled trials. Pharmacol Res (2017) 115:218–23. 
doi:10.1016/j.phrs.2016.11.035 
7. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, 
et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations 
from the National Institute on Aging-Alzheimer’s Association workgroups 
on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement (2011) 
7(3):263–9. doi:10.1016/j.jalz.2011.03.005 
8. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A stan-
dard procedure for creating a frailty index. BMC Geriatr (2008) 8:24. 
doi:10.1186/1471-2318-8-24 
9. Kelaiditi E, Canevelli M, Andrieu S, Del Campo N, Soto ME, Vellas B, et al. 
Frailty index and cognitive decline in Alzheimer’s disease: data from the impact 
of cholinergic treatment use study. J Am Geriatr Soc (2016) 64(6):1165–70. 
doi:10.1111/jgs.13956 
10. Canevelli M, Cesari M, Remiddi F, Trebbastoni A, Quarata F, Vico C, et al. 
Promoting the assessment of frailty in the clinical approach to cognitive 
disorders. Front Aging Neurosci (2017) 9:36. doi:10.3389/fnagi.2017.00036 
11. Cesari M, Gambassi G, van Kan GA, Vellas B. The frailty phenotype and the 
frailty index: different instruments for different purposes. Age Ageing (2014) 
43(1):10–2. doi:10.1093/ageing/aft160 
Conflict of Interest Statement: MCesari has received honoraria for presentations 
at scientific meetings and/or research fundings from Nestlé and Pfizer. He is 
involved in the coordination of an Innovative Medicines Initiative-funded project 
[including partners from the European Federation Pharmaceutical Industries 
and Associates (Sanofi, Novartis, Servier, GSK, Lilly)]. The other authors have no 
conflict of interest to declare.
Copyright © 2017 Canevelli, Trebbastoni, Quarata, D’Antonio, Cesari, de Lena and 
Bruno. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
